Can a new drug replace surgery for stage 0 cervical cancer? Here's the promise
ICMR has licensed the anti-HPV candidate SHetA2 to Emcure Pharmaceuticals for further development. The move could open a non-surgical path for treating precancerous cervical lesions, though clinical proof is still awaited.
The Indian Council of Medical Research (ICMR) has licensed SHetA2, a first-in-class anti-HPV therapeutic candidate, to Pune-based Emcure Pharmaceuticals for further development.
The drug, developed through a collaboration between scientists at ICMR's National Institute of Cancer Prevention and Research (NICPR) and the University of Oklahoma's Stephenson Cancer Center in the US, is designed to selectively destroy HPV-induced precancerous and cervical cancer cells while sparing healthy tissue.
If future clinical trials establish its safety and effectiveness, SHetA2 could become one of the first targeted drug therapies to treat cervical intraepithelial neoplasia (CIN) – the precancerous changes that precede cervical cancer – without the need for surgery.
The development is significant because CIN is detected increasingly through screening programmes, giving doctors an opportunity to intervene before cancer develops.
India has one of the world's highest cervical cancer burdens. According to the World Health Organisation (WHO), cervical cancer is among the most preventable cancers through HPV vaccination and regular screening.
Yet the disease remains the country's second most common cancer among women, after breast cancer, with nearly 80,000 new cases and more than 42,000 deaths every year.
Limited screening coverage, delayed diagnosis and uneven access to preventive healthcare continue to keep the burden high despite the availability of vaccines.
In a significant public health push, the government began offering free HPV vaccinations to 14-year-old girls on February 28 this year as part of a nationwide effort to reduce cervical cancer deaths.
This programme uses the vaccine Gardasil-4 and targets a large cohort: an estimated 1.15 crore girls in this age group across India.
BEYOND SURGERY
Cervical intraepithelial neoplasia is graded according to the severity of abnormal cell changes. CIN 1 is mild and often resolves on its own. CIN 2 carries a higher risk of progression, while CIN 3 is considered severe and has the greatest likelihood of developing into invasive cancer if left untreated.
Stage 0 cervical cancer, also known as carcinoma in situ, falls at this pre-invasive stage, when abnormal cells remain confined to the surface lining of the cervix.
Current treatment aims to remove these abnormal cells before they spread deeper into tissue. While the procedures are successful in preventing cancer, they are not without drawbacks.
"As a surgical oncologist, cervical cancer is a pressing public health challenge we face daily in India," said Dr Sandeep Nayak, head oncologist at MACS-Renova Oncology Institute, KIMS Hospital in Bengaluru.
Calling ICMR's move to license SHetA2 "a monumental leap forward in translational research", he said the therapy represents a shift "from surgical destruction to non-invasive medical management."
That distinction could be particularly important for women diagnosed in their reproductive years.
Unlike surgery, which removes part of the cervix, a targeted drug could potentially eliminate abnormal HPV-driven cells while preserving healthy cervical tissue. If the therapy is eventually available as an oral medicine or a locally administered treatment, it may reduce the need for invasive procedures and their possible effects on future pregnancies.
The approach also reflects a broader trend in cancer treatment: replacing tissue removal wherever possible with precision therapies that target diseased cells while minimising damage to healthy organs.
PROMISE, NOT PROOF
Even as researchers describe SHetA2 as a potential breakthrough, experts caution that it is not yet ready for clinical use.
The technology has now entered the crucial phase of drug development, where rigorous clinical trials will determine whether the laboratory findings can be reproduced safely and consistently in patients.
Researchers will need to establish the optimal dose, assess side effects, and compare outcomes with existing surgical treatments before regulators can consider approval.
That makes the announcement an important scientific milestone rather than an immediate change in clinical practice.
Scientists are also watching the drug for another reason. High-risk human papillomavirus (HPV), the virus responsible for almost all cervical cancers, is also implicated in cancers affecting the anus, penis and parts of the head and neck.
If SHetA2 successfully targets HPV-driven disease in the cervix, the same biological approach could eventually be explored in other HPV-associated precancerous conditions and cancers.
The Indian Council of Medical Research (ICMR) has licensed SHetA2, a first-in-class anti-HPV therapeutic candidate, to Pune-based Emcure Pharmaceuticals for further development.
The drug, developed through a collaboration between scientists at ICMR's National Institute of Cancer Prevention and Research (NICPR) and the University of Oklahoma's Stephenson Cancer Center in the US, is designed to selectively destroy HPV-induced precancerous and cervical cancer cells while sparing healthy tissue.
If future clinical trials establish its safety and effectiveness, SHetA2 could become one of the first targeted drug therapies to treat cervical intraepithelial neoplasia (CIN) – the precancerous changes that precede cervical cancer – without the need for surgery.
The development is significant because CIN is detected increasingly through screening programmes, giving doctors an opportunity to intervene before cancer develops.
India has one of the world's highest cervical cancer burdens. According to the World Health Organisation (WHO), cervical cancer is among the most preventable cancers through HPV vaccination and regular screening.
Yet the disease remains the country's second most common cancer among women, after breast cancer, with nearly 80,000 new cases and more than 42,000 deaths every year.
Limited screening coverage, delayed diagnosis and uneven access to preventive healthcare continue to keep the burden high despite the availability of vaccines.
In a significant public health push, the government began offering free HPV vaccinations to 14-year-old girls on February 28 this year as part of a nationwide effort to reduce cervical cancer deaths.
This programme uses the vaccine Gardasil-4 and targets a large cohort: an estimated 1.15 crore girls in this age group across India.
BEYOND SURGERY
Cervical intraepithelial neoplasia is graded according to the severity of abnormal cell changes. CIN 1 is mild and often resolves on its own. CIN 2 carries a higher risk of progression, while CIN 3 is considered severe and has the greatest likelihood of developing into invasive cancer if left untreated.
Stage 0 cervical cancer, also known as carcinoma in situ, falls at this pre-invasive stage, when abnormal cells remain confined to the surface lining of the cervix.
Current treatment aims to remove these abnormal cells before they spread deeper into tissue. While the procedures are successful in preventing cancer, they are not without drawbacks.
"As a surgical oncologist, cervical cancer is a pressing public health challenge we face daily in India," said Dr Sandeep Nayak, head oncologist at MACS-Renova Oncology Institute, KIMS Hospital in Bengaluru.
Calling ICMR's move to license SHetA2 "a monumental leap forward in translational research", he said the therapy represents a shift "from surgical destruction to non-invasive medical management."
That distinction could be particularly important for women diagnosed in their reproductive years.
Unlike surgery, which removes part of the cervix, a targeted drug could potentially eliminate abnormal HPV-driven cells while preserving healthy cervical tissue. If the therapy is eventually available as an oral medicine or a locally administered treatment, it may reduce the need for invasive procedures and their possible effects on future pregnancies.
The approach also reflects a broader trend in cancer treatment: replacing tissue removal wherever possible with precision therapies that target diseased cells while minimising damage to healthy organs.
PROMISE, NOT PROOF
Even as researchers describe SHetA2 as a potential breakthrough, experts caution that it is not yet ready for clinical use.
The technology has now entered the crucial phase of drug development, where rigorous clinical trials will determine whether the laboratory findings can be reproduced safely and consistently in patients.
Researchers will need to establish the optimal dose, assess side effects, and compare outcomes with existing surgical treatments before regulators can consider approval.
That makes the announcement an important scientific milestone rather than an immediate change in clinical practice.
Scientists are also watching the drug for another reason. High-risk human papillomavirus (HPV), the virus responsible for almost all cervical cancers, is also implicated in cancers affecting the anus, penis and parts of the head and neck.
If SHetA2 successfully targets HPV-driven disease in the cervix, the same biological approach could eventually be explored in other HPV-associated precancerous conditions and cancers.
The Indian Council of Medical Research (ICMR) has licensed SHetA2, a first-in-class anti-HPV therapeutic candidate, to Pune-based Emcure Pharmaceuticals for further development.
The drug, developed through a collaboration between scientists at ICMR's National Institute of Cancer Prevention and Research (NICPR) and the University of Oklahoma's Stephenson Cancer Center in the US, is designed to selectively destroy HPV-induced precancerous and cervical cancer cells while sparing healthy tissue.
If future clinical trials establish its safety and effectiveness, SHetA2 could become one of the first targeted drug therapies to treat cervical intraepithelial neoplasia (CIN) – the precancerous changes that precede cervical cancer – without the need for surgery.
The development is significant because CIN is detected increasingly through screening programmes, giving doctors an opportunity to intervene before cancer develops.
India has one of the world's highest cervical cancer burdens. According to the World Health Organisation (WHO), cervical cancer is among the most preventable cancers through HPV vaccination and regular screening.
Yet the disease remains the country's second most common cancer among women, after breast cancer, with nearly 80,000 new cases and more than 42,000 deaths every year.
Limited screening coverage, delayed diagnosis and uneven access to preventive healthcare continue to keep the burden high despite the availability of vaccines.
In a significant public health push, the government began offering free HPV vaccinations to 14-year-old girls on February 28 this year as part of a nationwide effort to reduce cervical cancer deaths.
This programme uses the vaccine Gardasil-4 and targets a large cohort: an estimated 1.15 crore girls in this age group across India.
BEYOND SURGERY
Cervical intraepithelial neoplasia is graded according to the severity of abnormal cell changes. CIN 1 is mild and often resolves on its own. CIN 2 carries a higher risk of progression, while CIN 3 is considered severe and has the greatest likelihood of developing into invasive cancer if left untreated.
Stage 0 cervical cancer, also known as carcinoma in situ, falls at this pre-invasive stage, when abnormal cells remain confined to the surface lining of the cervix.
Current treatment aims to remove these abnormal cells before they spread deeper into tissue. While the procedures are successful in preventing cancer, they are not without drawbacks.
"As a surgical oncologist, cervical cancer is a pressing public health challenge we face daily in India," said Dr Sandeep Nayak, head oncologist at MACS-Renova Oncology Institute, KIMS Hospital in Bengaluru.
Calling ICMR's move to license SHetA2 "a monumental leap forward in translational research", he said the therapy represents a shift "from surgical destruction to non-invasive medical management."
That distinction could be particularly important for women diagnosed in their reproductive years.
Unlike surgery, which removes part of the cervix, a targeted drug could potentially eliminate abnormal HPV-driven cells while preserving healthy cervical tissue. If the therapy is eventually available as an oral medicine or a locally administered treatment, it may reduce the need for invasive procedures and their possible effects on future pregnancies.
The approach also reflects a broader trend in cancer treatment: replacing tissue removal wherever possible with precision therapies that target diseased cells while minimising damage to healthy organs.
PROMISE, NOT PROOF
Even as researchers describe SHetA2 as a potential breakthrough, experts caution that it is not yet ready for clinical use.
The technology has now entered the crucial phase of drug development, where rigorous clinical trials will determine whether the laboratory findings can be reproduced safely and consistently in patients.
Researchers will need to establish the optimal dose, assess side effects, and compare outcomes with existing surgical treatments before regulators can consider approval.
That makes the announcement an important scientific milestone rather than an immediate change in clinical practice.
Scientists are also watching the drug for another reason. High-risk human papillomavirus (HPV), the virus responsible for almost all cervical cancers, is also implicated in cancers affecting the anus, penis and parts of the head and neck.
If SHetA2 successfully targets HPV-driven disease in the cervix, the same biological approach could eventually be explored in other HPV-associated precancerous conditions and cancers.
